With 830 women dying every day from preventable causes related to pregnancy and childbirth, and over 16,000 children under age five dying daily, Bayer and the White Ribbon Alliance today released critical policy recommendations and launched community programs to support the reduction and prevention of maternal, newborn and child mortality in two developing countries.1,2
Established through a three-year $1.3 million commitment from Bayer, these programs will expand work conducted by White Ribbon Alliance in Bangladesh and Zimbabwe to support the United Nations Secretary General’s Every Woman Every Child movement.
This announcement comes at the one-year anniversary of the Bayer/White Ribbon Alliance commitment in support of the Every Woman Every Child movement and will contribute to the success of the Sustainable Development Goals.
To view the multimedia release go to:
http://www.multivu.com/players/English/77126510-bayer-white-ribbon-alliance-self-care/
Syneron Medical Ltd., the leading global aesthetic device company, announced to a group of international media its new activities and enhanced global commitment to developing the non-invasive body shaping market, one of the fastest growing segments in the global aesthetic medical device market. The press conference took place at the Academy of Medical Sciences in London, just prior to the opening of the BODY Conference and Exhibition, which took place in London on November 3-4, 2012 and for which Syneron was the main sponsor.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58631-body-shaping-by-syneron
Every spring, allergies take control of the lives of millions of Americans, affecting their work, their family time and even how well they sleep at night. Something else affects those millions of allergy sufferers, according to a new survey: big misconceptions about allergies that may keep people from getting needed relief.
To help put those misconceptions about allergies to rest, Sanofi is teaming up with science educator and television personality Adam Savage, along with allergist Dr. Neeta Ogden, to dispel them with credible information. The goal: help the 50 million allergy sufferers in America get the facts they need to understand and treat their allergies and take back control of their lives.
To view the multimedia release go to:
https://www.multivu.com/players/English/8255452-sanofi-allergy-misconceptions-facts-adam-savage/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. As LLS leads the charge to find cures for cancer patients, this new funding, along with ongoing investment in LLS’s aggressive research agenda, brings LLS’s total commitment to blood cancer research to more than $1 billion. The investment has led to the development of nearly every therapy currently used to treat the blood cancers.
Along with these new research grants, LLS remains committed to collaborating with biotechnology companies through its innovative Therapy Acceleration Program® (TAP), a model pioneered by LLS in the cancer arena in recognition that traditional research approaches weren’t yielding treatments and cures fast enough for patients. LLS commits approximately $13 million a year to its TAP initiatives. As part of the 24 current such collaborations, LLS recently initiated new investments with Kite Pharma and OncoPep.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554852-lls-cancer-research-funding/
The Center For Aesthetics https://thecenterforaesthetics.com ~ 800-575-8337 ~ "True beauty shines from the inside out." Dr. Catherine Durboraw shares the story and passion of CFA Beauty premier aesthetic medical centers in Scottsdale, Jackson Hole, Idaho Falls.
The first thing Cathy’s long-time patients say is that they feel seen: “She really sees me. She studies my face carefully and helps me imagine what’s possible.” The first meeting, and each one after is distinguished by a patients-first devotion. We’re your partner all along the journey.
CFA Beauty
Medical Spa & Plastic Surgery
https://thecenterforaesthetics.com/
Following the unprecedented Gore REDUCE Clinical Study conclusion that closure of patent foramen ovale (PFO) can prevent recurrent ischemic strokes, W. L. Gore & Associates, Inc. (Gore) has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication for its GORE® CARDIOFORM Septal Occluder. The device, already approved for closure of atrial septal defects (ASDs) up to 17 mm, is now also approved for the closure of PFO to reduce the risk of recurrent ischemic stroke in certain patients.*
To view the multimedia release go to:
https://www.multivu.com/players/English/8301551-gore-cardioform-septal-occluder-fda-approval/
Today, WebMD released In Their Own Words: Moving Beyond Migraine with Robin Roberts, a new five-part video series that sheds light on the debilitating nature of migraine and the impact it has on all aspects of a sufferer’s personal and professional life.
To learn more about treatments and the individuals featured in In Their Own Words: Moving Beyond Migraine with Robin Roberts, visit: to www.webmd.com/insidemigraines.
Moving Beyond Migraine follows the lives of Jennifer, a public school administrator who has lived with intense migraine headaches for over 20 years; Kate, a 20-year-old college student with debilitating migraines that have run in her family for generations; Melanie, whose intense migraine condition has altered the dynamics of her nine year marriage; and Lynn, who after suffering from migraine for 50 years, shares how a clinical trial for a new treatment called CGRP targeted therapy is finally providing her with some relief.
To view the multimedia release go to:
https://www.multivu.com/players/English/7579759-robin-roberts-moving-beyond-migraine/
Today, Brother International Corporation, the leader in laser printing in the small office, home office market, announced its newest line of monochrome laser printers and all-in-ones. From work-from-home-warriors and small-office-heroes to trusted school administrators and busy medical practices, Brother has a proven track record of providing the most reliable printer solutions on the market, and today the best got even better.
The new lineup includes five printers and four all-in-ones to address the evolving needs of the busy home or small office, including the first Brother XL Extended Print laser models that include up to two years of toner in the box. Printers in the new lineup offer fastest-in-class print speeds, high-quality prints, and superb reliability, all while keeping budget in mind.
To view the multimedia release go to:
https://www.multivu.com/players/English/8253851-brother-monochrome-laser-printers-all-in-one/
Currently exhibited art works of New York
City artist Marko Stout. Marko Stout is a contemporary New York City
artist best known for his urban female figurative works. He holds
advanced degrees in anatomy and medicine- drawing inspiration from many
artists such as Francis Bacon, Andy Warhol, Lichtenstein, contemporary
New York street art and utilizing his past skills as a medical
illustrator Marko creates a stimulating narrative of the contemporary
urban female. His subjects often appear in a moderate state of
distress, overwhelmed by their modern high tech and stressed
environment, while maintaining a cool elegant and sexy demeanor of a
sophisticated twenty-first century city dweller. His works are now
featured in numerous fine art galleries of New York City, Chicago, San
Francisco and Miami, as well as London, Berlin, Australia and India. As
well as solo shows in the SOHO and Chelsea areas of New York. Marko Stout 2012 Collection, Marko Stout Art Gallery, LLC, New York City. http://www.MarkoStout.com http://www.MarkoNYC.com
Today, WebMD released My Abuelita Told Me, a new five-part video series developed in partnership with Dr. Juan Rivera (“Dr. Juan”), a board-certified internist and cardiologist, who is well-known for his best-selling books and regular appearances on broadcast television. My Abuelita Told Me explores the reliability of the various home remedies, beliefs and established practices that beloved abuelitas (a.k.a. grandmas) have passed down through the generations, and Dr. Juan clarifies what is or isn’t accurate using medical science.
To view the multimedia release go to:
https://www.multivu.com/players/English/7579758-webmd-my-abuelita-told-me-bilingual-video-series/
Hunova, the first robotic gym for the rehabilitation and functional motor sense evaluation of lower limbs and trunk, has been officially launched in Genoa, Italy. The first 30 robots will be available from June in Europe and the USA. The technology was developed and patented at the IIT laboratories and has been launched on the market thanks to a 10 million euro investment from entrepreneur Sergio Dompè.
Hunova is a programmable robotic medical device that allows professionals in the geriatrics, neurology and sport rehabilitation field to cure and predict many neurological and orthopedic conditions. There are two main competitive advantages of this technology: Hunova is able to collect a significant amount of data on biomechanics, constantly monitoring the patient’s progress. Secondly, it provides direct support to the patient through a guiding robotic system, offering a wide range of rehabilitation protocols in the form of video games. It consists of two electromechanical platforms equipped with sensors, characterized by two degrees of freedom (feet and seat level). The device integrates the force sensors to adjust the interaction with the patient and a wireless sensor, which is placed on the patient’s trunk, allowing the physiotherapist to check the movement of the torso.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8108951-iit-movendo-launch-robot-hunova/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
